nach oben

Journal of Neuro-Oncology

Erschienen in:

27.11.2023 | Research

Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients

verfasst von: Berrin Benli Yavuz, Fahriye Kilinc, Gul Kanyilmaz, Meryem Aktan

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pyruvate kinase M2 (PKM2) is a key enzyme that catalyzes the irreversible and final step of glycolysis. It is closely associated with cancer development and progression. The relationship between PKM2 and prognosis in glioblastoma (GB) patients is unknown. The aim of this study was to measure PKM2 expression and evaluate its effect on prognosis in GB patients.

Methods

Patients who underwent radiotherapy (RT) for glioblastoma between 2010 and 2021 were evaluated immunohistochemically. A single pathologist evaluated pathology specimens of all patients. The intensity and extent of staining of tumor cells were scored. Patients were categorized as low and high PKM2.

Results

A total of 119 patients were evaluated. While 80.7% of the cases had a low score, 19.3% had a high PKM2 score. It was observed that the group with high PKM2 expression had lower performance, received more hypofractionated RT and received adjuvant chemotherapy (CT) less frequently. Median overall survival (OS) was 15.77 months in the low PKM2 expression group and 6.50 months in the high PKM2 group. In univariate analyses, PKM2 expression, age, performance status, type of surgery, RT scheme, and concurrent and adjuvant CT were prognostic factors in predicting OS. In multivariate analyses, PKM2 expression, type of surgery, RT scheme and receiving adjuvant CT were prognostic factors for OS.

Conclusion

PKM2 is an independent prognostic factor for survival and is associated with poor prognosis in GBM patients treated with radiotherapy. It may be a potential therapeutic target for anticancer therapy.

Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J, Ghia AJ, Zhu C, Sulman EP, de Groot JF, Heimberger AB, McGovern SL, Grassberger C, Shih H, Ellsworth S, Grosshans DR (2021) Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol 23(2):284–294. https://doi.org/10.1093/neuonc/noaa182CrossRefPubMed

Guclu E, Ayan IC (2023) Investigation of the Anticancer activity of DCZ0415, a small molecular inhibitor of TRIP13, in U87 Human Glioblastoma Multiforme Cells. Selcuk Med J 39(1):12–18. https://doi.org/10.30733/std.2023.01587CrossRef

Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C (2020) A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14 – 01). Neuro Oncol 22(12):1851–1861. https://doi.org/10.1093/neuonc/noaa107CrossRefPubMedPubMedCentral

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7CrossRefPubMed

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS et al (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16(1):142. https://doi.org/10.1186/s12967-018-1507-6CrossRefPubMedPubMedCentral

Lee HJ, Han HJ, Lee JY, Son WC (2020) PKM2 in Canine Mammary tumors: parallels to human Breast Cancer. Comp Med 70(4):349–354. https://doi.org/10.30802/AALAS-CM-20-000013CrossRefPubMedPubMedCentral

Yin C, Lu W, Ma M, Yang Q, He W, Hu Y, Xia L (2020) Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in Colorectal cancer. Oncol Lett 20(6):312.CrossRefPubMedPubMedCentral

Verma H, Cholia RP, Kaur S, Dhiman M, Mantha AK (2021) A short review on cross-link between pyruvate kinase (PKM2) and Glioblastoma Multiforme. Metab Brain Dis 36(5):751–765. https://doi.org/10.1007/s11011-021-00690-yCrossRefPubMed

Cui R, Shi XY (2015) Expression of pyruvate kinase M2 in human Colorectal cancer and its prognostic value. Int J Clin Exp Pathol 8(9):11393–11399PubMedPubMedCentral

10.

Dayton TL, Jacks T, Vander Heiden MG (2016) PKM2, cancer metabolism, and the road ahead. EMBO Rep 17(12):1721–1730. https://doi.org/10.15252/embr.201643300CrossRefPubMedPubMedCentral

11.

Huang C, Huang Z, Bai P, Luo G, Zhao X, Wang X (2018) Expression of pyruvate kinase M2 in human Bladder cancer and its correlation with clinical parameters and prognosis. Onco Targets Ther 11:2075–2082. https://doi.org/10.2147/OTT.S152999CrossRefPubMedPubMedCentral

12.

Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F (2019) PKM2, function and expression and regulation. Cell Biosci 9:52. https://doi.org/10.1186/s13578-019-0317-8CrossRefPubMedPubMedCentral

13.

Li H, Yan M, Wu X, Wang Y, Huang L (2021) Expression and clinical significance of pyruvate kinase M2 in Breast cancer: a protocol for meta-analysis and bioinformatics validation analysis. Med (Baltim) 100(18):e25545. https://doi.org/10.1097/MD.0000000000025545CrossRef

14.

Yu G, Yu W, Jin G, Xu D, Chen Y, Xia T, Yu A, Fang W, Zhang X, Li Z, Xie K (2015) PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol Cancer 14:193. https://doi.org/10.1186/s12943-015-0462-6CrossRefPubMedPubMedCentral

15.

Lin Y, Zhai H, Ouyang Y, Lu Z, Chu C, He Q, Cao X (2019) Knockdown of PKM2 enhances radiosensitivity of Cervical cancer cells. Cancer Cell Int 19:129. https://doi.org/10.1186/s12935-019-0845-7CrossRefPubMedPubMedCentral

16.

Zhu H, Luo H, Zhu X, Hu X, Zheng L, Zhu X (2017) Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis. Oncotarget 8(1):1628–1640. https://doi.org/10.18632/oncotarget.13703CrossRefPubMed

17.

Long L, Chen M, Yuan Y, Ming AL, Guo W, Wu K, Chen H (2020) High expression of PKM2 synergizes with PD-L1 in Tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. J Cancer 11(15):4442–4452. https://doi.org/10.7150/jca.42610CrossRefPubMedPubMedCentral

18.

Lockney NA, Zhang M, Lu Y, Sopha SC, Washington MK, Merchant N, Zhao Z, Shyr Y, Chakravarthy AB, Xia F (2015) Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) expression is Associated with overall survival in pancreatic ductal adenocarcinoma. J Gastrointest Cancer 46(4):390–398. https://doi.org/10.1007/s12029-015-9764-6CrossRefPubMedPubMedCentral

19.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4CrossRefPubMedPubMedCentral

20.

Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B (2020) Response Assessment in Neuro-Oncology Criteria for Gliomas: practical Approach using Conventional and Advanced techniques. AJNR Am J Neuroradiol 41(1):10–20. https://doi.org/10.3174/ajnr.A6358CrossRefPubMedPubMedCentral

21.

Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO (2013) Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS ONE 8(2):e57610. https://doi.org/10.1371/journal.pone.0057610CrossRefPubMedPubMedCentral

22.

Sun H, Zhu A, Zhang L, Zhang J, Zhong Z, Wang F (2015) Knockdown of PKM2 suppresses Tumor Growth and Invasion in Lung Adenocarcinoma. Int J Mol Sci 16(10):24574–24587. https://doi.org/10.3390/ijms161024574CrossRefPubMedPubMedCentral

23.

Lu W, Cao Y, Zhang Y, Li S, Gao J, Wang XA, Mu J, Hu YP, Jiang L, Dong P, Gong W, Liu Y (2016) Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer. Sci Rep 6:26351. https://doi.org/10.1038/srep26351CrossRefPubMedPubMedCentral

24.

Gao X, Wang H, Yang JJ, Chen J, Jie J, Li L, Zhang Y, Liu ZR (2013) Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. J Biol Chem 288(22):15971–15979. https://doi.org/10.1074/jbc.M112.448753CrossRefPubMedPubMedCentral

25.

Cholia RP, Dhiman M, Kumar R, Mantha AK (2018) Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes. Metab Brain Dis 33(4):1307–1326. https://doi.org/10.1007/s11011-018-0233-3CrossRefPubMed

26.

Burgenske DM, Yang J, Decker PA, Kollmeyer TM, Kosel ML, Mladek AC, Caron AA, Vaubel RA, Gupta SK, Kitange GJ, Sicotte H, Youland RS, Remonde D, Voss JS, Fritcher EGB, Kolsky KL, Ida CM, Meyer FB, Lachance DH, Parney IJ, Kipp BR, Giannini C, Sulman EP, Jenkins RB, Eckel-Passow JE, Sarkaria JN (2019) Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro Oncol 21(11):1458–1469. https://doi.org/10.1093/neuonc/noz129CrossRefPubMedPubMedCentral

27.

Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C (2020) IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer 122(11):1580–1589. https://doi.org/10.1038/s41416-020-0814-xCrossRefPubMedPubMedCentral

Titel: Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients
verfasst von: Berrin Benli Yavuz
Fahriye Kilinc
Gul Kanyilmaz
Meryem Aktan
Publikationsdatum: 27.11.2023
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04521-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Preoperative assessment of eloquence in neurosurgery: a systematic review

Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis

Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer

Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [11C]methionine PET

Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy